2016•Cancer Chemotherapy and PharmacologyRequires access

Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation

Yasushi Yoshimura, Mitsue Kurasawa, Keigo Yorozu, Óscar Puig, Walter Bordogna, Naoki Harada

Open publisher page 27 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 27 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Alectinib, ALK inhibitor, Crizotinib, Mutation, Anaplastic lymphoma kinase, Cancer research, Azacitidine, Cell culture

Back to paper search Browse research topics Original source

Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation — Research Paper | ScholarLens